We examined the in vitro antiproliferative activity of BCL2-selective inhibitors in a wide range of lymphoma cell lines, including DLBCL, mantle cell lymphoma (MCL), Hodgkin lymphoma (HL), Burkitt lymphoma (BL), and anaplastic large cell lymphoma. This evidence concerns the gene BCL2 and anaplastic large cell lymphoma.